Several countries suspend inoculations but regulator says vaccine benefits outweigh its risks
The European Medicines Agency has said the Oxford/AstraZeneca Covid vaccine can continue to be used during an investigation into cases of blood clots that have prompted several European countries to pause their use of the shot.
The EMA said 30 cases of “thromboembolic events” or blood clots had been reported among 5 million people who had received the jab in Europe so far. “The vaccine’s benefits continue to outweigh its risks,” the regulator said in a statement.
Continue reading...